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INTRODUCTION
The endothelin (ET) system is thought to play important
roles in the emergence and maintenance of functions of vari-
ous organs during perinatal development, including the kid-
ney. It has been reported that expression of ET-1 increases in
these organs toward the later stages of embryonic development
(1, 2). The expression of ET receptors has also been shown to
increase around the time of birth in animal models (3). The
evidence suggests an influential role for the ET system dur-
ing normal physiologic growth and development of the kid-
ney, and evokes the possibility of an influence of ET-1 recep-
tor antagonists during postnatal maturation and develop-
ment of the kidney. However, it is still unknown whether
endogenous activation of the paracrine ET systems plays a
physiologic role in renal development. 
An unexpected role of the ET system in embryonic and
fetal development has been recently discovered and appears
to be essential for cardiovascular and neuronal crest-derived
cell differentiation (4, 5). Despite the definitive demonstra-
tions of a crucial role of the ET system during early devel-
opment, little is known about the importance of the ET sys-
tem during the perinatal period, including the late embry-
onic and neonatal stages.
It is now well-accepted that the growth impairment of
developing organs is often the result of an imbalance between
the rate of cell proliferation and that of apoptosis. Our pre-
vious study (6) showed that ET inhibition by selective en-
dothelin A receptor (ETAR) blockade decreased apoptosis
and the expression of its related genes in the developing rat
heart. The ETAR antagonist also decreased cellular prolifera-
tion. The decreased cell turnover due to the ETAR antagonist
in the developing rat heart may account for neonatal cardiac
growth impairment. These findings indicate the likelihood
of important functions for the ETAR antagonist in the devel-
opment of the kidney, which is another hemodynamically
important system. Thus, an imbalance between cell prolifer-
ation and apoptosis due to ETAR blockade might contribute
to the normal growth and development of the kidney dur-
ing the perinatal period.
In this study, we selected the developing kidney model of
the neonate rat and investigated the roles of the ET system in
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Endothelin A Receptor Blockade Influences Apoptosis and Cellular
Proliferation in the Developing Rat Kidney
Endothelin systems are believed to play important roles in the emergence and
maintenance of functions of various organs during perinatal development, includ-
ing the kidney. The present study was designed to investigate the roles of endothe-
lin systems on physiologic renal growth and development. Newborn rat pups were
treated with either Bristol-Myers Squibb-182874 (30 mg/kg/day), a selective endothe-
lin A receptor (ETAR) antagonist, or vehicle for 7 days. To identify cellular changes,
kidneys were examined for apoptotic cells by terminal deoxynucleotide transferase-
mediated nick-end labeling stain and proliferating cell nuclear antigen (PCNA) by
immunohistochemical (IHC) stain. To clarify the molecular control of these process-
es, immunoblots and reverse transcriptase-polymerase chain reaction for Clusterin,
Bcl-2, Bcl-XL, Bax, and p53 were performed. ETAR antagonist treatment resulted
in reduced kidney weights, decreased PCNA-positive proliferating cells, and increas-
ed apoptotic cells. The protein expressions of renal Bcl-XL and Bax in the ETAR
antagonist-treated group were significantly decreased, whereas the mRNA expres-
sions of these genes were not changed. There were no significant differences in
the expressions of Clusterin, Bcl-2, and p53. In conclusion, inhibition of endoge-
nous endothelins impairs renal growth, in which decreased cellular proliferation,
increased apoptosis and decreased expressions of renal Bcl-XL and Bax are pos-
sibly implicated.
Key Words : Endothelins; Growth and Development; Apoptosis; Cell Proliferation; Clusterin; Bcl-2; Bcl-XL;
Bax; p53; Kidney
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the renal growth and development. The experimental app-
roach consisted of inhibiting endogenous ET by the chronic
administration of Bristol-Myers Squibb (BMS)-182874, a
competitive, selective, and orally active ETAR antagonist, to
the neonatal rat pups. The effects of the ETAR antagonist on
cellular proliferation and apoptosis in the neonatal rat kidney
were investigated. In addition, to clarify the molecular control
of these processes, the changes in expression of various regu-
latory genes at the protein and mRNA levels by the ETAR
antagonist were determined. 
MATERIALS AND METHODS
Animal preparation
Forty-two neonatal rat pups from seven pregnant Sprague-
Dawley rats were breastfed by their own mother throughout
the study. The newborn rats were divided into two groups
and a dose of 30 mg/kg of BMS-182874 (BMS Korea, Seoul,
Korea) (BMS group) or 10 cc/kg of normal saline (control
group) were fed to the rat pups via an orogastric tube for 7
days, respectively. After 7 days, their kidneys were harvested
and RNA analysis, protein assays, and immunohistochemi-
cal staining for cell proliferation and apoptosis were performed.
The protocols for the animal experimentation and the han-
dling of animals were approved by the Animal Care Com-
mittee of the Korea University Guro Hospital. 
Immunohistochemical stain 
Immunostaining was performed on paraffin sections as des-
cribed previously (7, 8). The proliferating cell nuclear anti-
gen (PCNA) cells and terminal deoxynucleotide transferase-
mediated nick-end labeling (TUNEL)-positive apoptotic
cells were detected using the avidin-biotin immunoperoxi-
dase method (Vectastain ABC kit, Burlingame, CA, U.S.A.)
and the TACS TM 2 TdT In Situ Apoptosis Detection Kit
(Trevigen, Gaithersburg, MD, U.S.A.), respectively. We com-
pared three slides of each kidney in both groups using a light
microscope (400×). The number of PCNA-positive cells
and TUNEL-positive apoptotic cells were measured by count-
ing 15 areas (250×250 μ m) and obtaining the average. The
PCNA-positive cells were counted if they had a central ovoid
nucleus with a clear zone and abundant eosinophilic cyto-
plasm. Only morphologically distinct nuclei that stained
positively by the TUNEL assay were counted as apoptotic. 
Isolation of kidney RNA and protein
Each five left kidneys of the control and the BMS group
were selected for RNA analysis and protein assays. The TRI-
REAGENT (Molecular Research Center, Cincinnati, OH,
U.S.A.) method was used for RNA and protein isolation,
according to the recommendations of the manufacturer, and
prepared as previously described (8). 
cDNA synthesis by reverse transcription (RT) and 
polymerase chain reaction (PCR) 
Oligo dT primed 1st strand cDNA was synthesized from
the template RNA (1 μ g) by using a cDNA Synthesis Kit
(Boehringer Mannheim Corp., Indianapolis, IN, U.S.A.). The
primers used in the PCR reaction are presented in Table 1. The
PCR was carried out with a different mode of time and tem-
perature for each reaction period by using a Perkin Elmer Cetus
DNA Thermal Cycler (Model 2400, Foster City, CA, U.S.A.).
These amplified PCR products were visible as fluorescent bands
at regular intervals under ultraviolet light after performing
electrophoresis in 2% agarose gel and ethidium bromide stain-
ing. The Polaroid photographs were scanned using an Epson
GT-9500 (Seiko Corp., Nagano, Japan) and the pictures were
quantified by a densitometer (Image PC alpha 9, N.I.H.,
Bethesda, MD, U.S.A.), and the values were revised glycer-
aldehyde-3-phosphate dehydrogenase(GAPDH). 
Genes Primers PCR product Sequence
GAPDH Forward 5′ -AATGCATCCTGCACCACCAA-3′ 515 bp
Reverse 5′ -GTAGCCATATTCATTGTCATA-3′
Clusterin Forward 5′ -CGGGTACCGACAATGAGCTCCA-3′ 310 bp
Reverse 5′ -GGCCGCGGCCACTTCTGCAGAC-3′
Bcl-2 Forward 5′ -TGGGATACTGGATGAAGA-3′ 478 bp
Reverse 5′ -AGACAGCCAGGAGAAATCAAA-3′
Bcl-XL Forward 5′ -GGTGGTTGACTTTCTCTCCTAC-3′ 491 bp
Reverse 5′ -GAAAAGTATCCCAGCCGCC-3′
Bax Forward 5′ -GACAVVTGAGCTGACCRRGG-3′ 310 bp
Reverse 5′ -GAGGAAGTCCAGTGTCCAGC-3′
p53 Forward 5′ -CTGAGGTCGGCTCCGACTATACCACTATCC-3′ 360 bp
Reverse 5′ -CTGATTCAGCTCTCGGAACATCTCGAAGCG-3′
Table 1. The primer sequences and the expected product sizes for RT-PCR analysis
RT-PCR, reverse transcription-polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.140 K.H. Yoo, H.E. Yim, G.Y. Jang, et al.
Immunoblot analysis 
Immunoblots were performed as in previous studies (6-8).
Briefly, equal amounts of 5-15 μ g of proteins were subjected
to 10% SDS-polyacrylamide gels and then transferred onto
nitrocellulose membranes (Amersham Life Science, Buck-
inghamshire, U.K.). The membrane was first blotted for
the antibodies directed against clusterin, Bcl-2, Bcl-XL, Bax,
and p53. Then, it was reblotted for α -tubulin (1:1,000 dilu-
tion; Oncogene, Boston, MA, U.S.A.) to control equal load-
ing. The characteristics of the antibodies directed against
clusterin, Bcl-2, Bcl-XL, Bax, and p53 are listed in Table 2.
The relative densities of these antibodies versus α -tubulin
bands were measured by a computerized densitometer (Image
PC alpha 9).
Statistical analysis
The results are expressed as the means±SEM. Differences
between groups were tested for their significance by using
the Student t-test and the Mann-Whitney rank sum test, and
a value of p<0.05 was considered statistically significant. 
Upstate Biotechnology (Lake Placid, NY, U.S.A.); R&D systems, Inc.
(Minneapolis, MN, U.S.A.); Calbiochem (La Jolla, CA, U.S.A.); BD Bio-
sciences (Los Angeles, CA, U.S.A.); Santa Cruz Biotechnology (Santa
Cruz, CA, U.S.A.); Oncogene Biotechnology (Boston, MA, U.S.A.).
Type Host Source Dilution
Clusterin Monoclonal Rabbit 1:400 Upstate
Bcl-2 Monoclonal Mouse 1:500 R&D
Bcl-XL Polyclonal Rabbit 1:1,000 Calbiochem
Bax Polyclonal Mouse 1:500 BD
p53 Polyclonal Mouse 1:1,000 Santacruz
Tubulin Monoclonal Mouse 1:1,000 Oncogen
Table 2. Characteristics and sources of clusterin, Bcl-2, Bcl-XL,
Bax, and p53 antibodies
Fig. 1. PCNA stains for proliferating cells in the control group (A) and the BMS group (B). PCNA-positive cells were rarely found in the BMS
group as compared with the control group. Cortical tubular epithelial and interstitial cell proliferations were decreased following treatment
with the ETA receptor antagonist as compared with the control group. Bar+0.1 μ m. Magnification: ×400.
A B
Fig. 2. TUNEL stains for apoptotic cells in the control group (A) and the BMS group (B). In the BMS group, TUNEL-positive apoptotic cells
were more frequently found in the dilated tubular epithelial cells, as compared with the control group. Bar+0.1 μ m. Magnification: ×400.
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RESULTS
Kidney weight 
On harvest, the average kidney weights were significantly
reduced in the BMS group (124±18 mg) as compared with
the control group (160±29 mg; p<0.05). 
PCNA
The PCNA-positive cells were found in both the tubules
and the interstitium of both groups. A small number of pro-
liferating glomerular cells and vascular cells were also ob-
served. However, the number of PCNA-positive cells was
decreased in the BMS group compared with the control group
(Fig. 1). The number of PCNA-positive cells was 19.5±0.3
in the control group and 12.9±1.1 in the BMS group in each
250×250 μ m field. There was a significant 33.8% reduc-
tion in the PCNA-positive cells in the BMS group (p<0.05).
Apoptosis 
TUNEL-positive apoptotic cells were rarely found in the
renal cortices of both groups. In the BMS group, apoptotic
cells were occasionally observed in the dilated tubular epithe-
lial cells and they were more frequently found as compared
with the control group (Fig. 2). The number of TUNEL-
positive apoptotic cells was 2.46±0.09 in the control group
and 2.79±0.12 in the BMS group in each field of 250×250
μ m, an increment of 13.4% (p<0.05).
Fig. 3. Representative expressions of clusterin mRNA and protein.  , control group;     , BMS group. (A) On the semi-quantitative RT-PCR,
the clusterin/GAPDH mRNA expressions were not different between the two groups. (B) On the immunoblot analysis, the clusterin/tubulin
protein expressions were not changed in the BMS group as compared with the control group.
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Fig. 4. Representative expressions of Bcl-2 mRNA and protein.     , control group;     , BMS group. (A) On the semi-quantitative RT-PCR,
the Bcl-2/GAPDH mRNA expression was not different between the two groups. (B) On the immunoblot analysis, the Bcl-2/tubulin protein
expression were not changed in the BMS group as compared with the control group.
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Expression of clusterin mRNA and protein 
The clusterin/GAPDH mRNA expressions were 0.73±
0.04 in the control group and 0.75±0.05 in the BMS group.
The clusterin/tubulin protein expression was not changed
in the BMS group (0.72±0.06) compared with the control
group (0.66±0.06; Fig. 3).
Expression of Bcl-2 mRNA and protein 
The Bcl-2/GAPDH mRNA expression was 0.97±0.03
in the BMS group and 0.96±0.03 in the control group. The
Bcl-2/tubulin protein expression was not changed in the BMS
group (1.12±0.27) compared with the control group (1.05
±0.18; Fig. 4). 
Expression of Bcl-XL mRNA and protein 
The Bcl-XL/GAPDH mRNA expression was 1.05±0.12
in the control group and 1.14±0.08 in the BMS group. The
Bcl-XL/tubulin protein expression was decreased significant-
ly in the BMS group (0.70±0.24) compared with the con-
trol group (1.04±0.09, p<0.05; Fig. 5). 
Expression of Bax mRNA and protein
The Bax/GAPDH mRNA expression was 0.98±0.13 in
the control group and 0.87±0.09 in the BMS group. In
addition, the Bax/tubulin protein expression was decreased
significantly in the BMS group (0.78±0.08) compared with
the control group (1.39±0.03, p<0.01; Fig. 6). 
Fig. 5. Representative expression of Bcl-XL mRNA and protein.     , control group;     , BMS group. (A) On the semi-quantitative RT-PCR,
the Bcl-XL/GAPDH mRNA expression were not different between the two groups. (B) On the immunoblot analysis, the Bcl-XL/tubulin pro-
tein expression was decreased significantly in the BMS group as compared with the control group.
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Fig. 6. Representative expression of Bax mRNA and protein.     , control group;     , BMS group. (A) On the semi-quantitative RT-PCR, the
Bax/GAPDH mRNA expression were not different between the two groups. (B) On the immunoblot analysis, the Bax/tubulin protein
expression was decreased significantly in the BMS group as compared with the control group.
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Expression of p53 mRNA and protein 
The p53/GAPDH mRNA expression was 0.92±0.07 in
the control group and 0.94±0.03 in the BMS group. The
p53/tubulin protein expression was not changed significant-
ly in the BMS group (1.49±0.18) compared with the con-
trol group (1.05±0.11, p=0.073; Fig. 7). 
DISCUSSION
The renin-angiogensin system (RAS) and the ET system
have features of the most potent vasopressor mechanisms iden-
tified to date. These neurohormones are regulated by the same
G protein-coupled receptors. It has been hypothesized that
angiotensin II (Ang II), the active peptide of the RAS, affects
the synthesis of ET-1, which in turn can influence the RAS
by acting at different steps. In keeping with this hypothesis,
the identification of the consensus sequences for jun in the
regulatory regions of the preproendothelin-1 gene has raised
the possibility of its transcriptional regulation by Ang II (9).
Ang II has been reported to augment pre-/pro-ET-1 expres-
sion not only in vascular endothelial cells, but also in non-
endothelial cells, including vascular smooth muscle cells,
myocardial cells, renal epithelial cells, and glomerular mesan-
gial cells (10, 11). With this in mind, Ang II may have its
cellular effects through the induction of ET. Therefore, it
could be speculated that Ang II is directly involved in the
development of tissue hypertrophy through the activation
of the Ang II type 1 receptor and furthermore, Ang II is indi-
rectly involved through the activation of the ET system. As
a consequence, it is likely that under pathophysiologic condi-
tions caused by the activation of the RAS, ET receptor an-
tagonists may be effective for ameliorating the hypertensive
phenotypes.
In our previous study, we demonstrated that Ang II mod-
ulates growth in a variety of tissues, including the kidney
and the heart (7, 8, 12, 13). Ang II inhibition by angiotensin
converting enzyme (ACE) inhibitor in the developing rat
kidney decreases the cellular proliferation and increases apop-
tosis, and this may account for neonatal renal growth impair-
ment (7, 8, 12-15). These results suggest that the RAS is
necessary for normal renal growth and development. So, ET-
1, like Ang II, is implicated in postnatal renal maturation
and development. 
The present in vivo animal study has demonstrated that
ET systems may play a role in renal growth impairment via
ETAR inhibition. In particular, the chronic administration
of ETAR antagonists diminished the number of PCNA-posi-
tive proliferating cells by 33.8% in cortical tubular epithelial
cells. Our previous studies demonstrated that ACE inhibi-
tion by enalapril decreased cellular proliferation in the devel-
oping rat kidney. The PCNA-positive proliferating cells were
also decreased significantly in the same cortical tubular epithe-
lial cells (12, 15). 
In the present study, we have shown here that TUNEL-
positive apoptotic cells were increased in the BMS-treated
group, and this was similar to the previous enalapril-treated
group. The apoptotic cells primarily occurred in the dilated
cortical tubules and the number was increased in the BMS-
treated group. Diminished kidney size was associated with
the lowered cellular proliferation rates, as well as with increas-
ed apoptosis. The long-term ET inhibition may have an effect
on the renal hemodynamics, as a result of the hypotension,
the microcirculation or the local ischemia seen in an in vivo
model. None of these effects were seen when using hydra-
lazine at the doses previously established to have equivalent
effects on blood pressure (7, 16). These experiments suggest
Fig. 7. Representative expression of p53 mRNA and protein.     , control group;     , BMS group. (A) On the semi-quantitative RT-PCR, the
p53/GAPDH mRNA expression was not different between the two groups. (B) On the immunoblot analysis, the p53/tubulin protein expres-
sion was not changed in the BMS group as compared with the control group.
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that the effects of ETAR antagonists on renal growth are medi-
ated through direct cell signaling rather than through the
secondary hemodynamic effects.
Apoptosis is a crucial event in various physiologic process-
es, such as embryogenesis, organ development, and cell pro-
liferation, as well as in pathologic processes, including auto-
immune disease and cancer development. These phenomena
are regulated by several genes. Of these genes, the clusterin
gene has important roles in various pathophysiologic pro-
cesses, including tissue remodeling, reproduction, lipid trans-
port, complement regulation, and apoptosis. Clusterin has
been shown to be one of the most potent inhibitors of apop-
tosis that was induced by a wide variety of stimuli. Our pre-
vious study (14) has indicated that the inhibition of Ang II
by an ACE inhibitor on the developing rat kidney decreased
clusterin protein expression. Thus, clusterin mRNA expres-
sion was increased as a secondary response to increased apop-
tosis and decreased its protein expression. However, in the
present study, the ETAR inhibition did not change the pro-
tein and mRNA expressions of clusterin. 
One of the major multigene families involved in the molec-
ular control of cell survival or death is the Bcl-2 gene family.
Members of the Bcl-2 gene family can form homo- or het-
ero-dimers, and the relative proportions of the anti-apoptot-
ic members, such as Bcl-2 or Bcl-XL and the pro-apoptotic
members, such as Bax are now thought to govern whether
the cell lives or dies after damage (17). 
During nephrogenesis, apoptosis tends to be inversely cor-
related with Bcl-2 expression. Bcl-2 is highly expressed early
in the embryonic kidney and its level decreases significantly
at later times such that its expression is normally low in the
postnatal kidney (18). Our previous study (14) has indicated
that the inhibition of Ang II by ACE inhibitor in the devel-
oping rat kidney decreased Bcl-2 protein expression. Bcl-2
mRNA expression was increased as a secondary response to
the increased apoptosis and this decreased its protein expres-
sion. However, in the present study, ETAR inhibition did
not change the Bcl-2 protein and mRNA expression. 
Expression studies have demonstrated that Bcl-XL was
predominantly expressed postnatally. Bcl-XL is five- to six-
fold more abundant in the adult kidney, brain, and thymus
than Bcl-2. Therefore, it also appears that Bcl-XL may play
an important role in the regulation of cell death during devel-
opment and tissue homeostasis. In the BMS-treated group,
we found that Bcl-XL protein expressions were significantly
decreased, as compared with the control group. The renal
apoptosis induced by ETAR inhibition in the developing kid-
ney was related with the decreased anti-apoptotic Bcl-XL pro-
tein expression, but the Bcl-XL mRNA expression was not
changed. Unfortunately, as compared with the control group,
the expression of proapoptotic Bax protein was decreased in
the BMS-treated group. This deregulated expression of Bax
and Bcl-XL was also found to impair the normal renal devel-
opmental processes (19, 20). Together these data can be ex-
plained in two ways. First, the Bcl-XL gene plays a more
important role than the Bax gene in the regulation of cell
death during the renal development. Alternatively, the in-
creased Bax protein degradation can be a conceivable possi-
bility without the change of mRNA expression (21).
p53 is a transcriptional factor that has effects on the cell
cycle arrest or apoptosis in response to a variety of stresses.
p53 is also a transcriptional modulator of the Bax gene that
promotes apoptosis. Additionally, a p53-negative response
element has been identified in the Bcl-2 gene, which pro-
tects from apoptosis. p53 is one of the representative apop-
tosis-promoting factors and, as has already been mentioned
in the results, the levels of expression of this gene appears to
be unaffected during the course of the apoptotic effect of the
ETAR antagonist in the developing kidney models.  
In summary, our results show an influential role of the ET
system for the normal physiologic growth and development
of the rat kidney, and this evokes the possibility of the influ-
ence of the ET-1 receptor antagonists on the postnatal mat-
uration and development of the kidney. Inhibition of the
endogenous ET production by chronic administration of an
ET-1 receptor antagonist to neonatal rat seems to impair the
renal growth, and in this process, the decrease of cellular pro-
liferation and the increase of apoptosis may play a role in renal
growth impairment. Especially, the Bcl-xL gene functions as
a dominant regulator of apopotic cell death in the develop-
ing rat kidney. Further studies are needed to look into the
renal growth factor systems that are involved in cellular pro-
liferation, which in turn control renal growth and develop-
ment by the ET system.
Although this experiment did not evaluate the short-term
outcomes, the exogenous ET-1 receptor antagonists are like-
ly to contribute to the normal growth and development of
kidney during the perinatal period. In the future, clinical
trials using ET-1 receptor antagonists in newborn infants,
investigators should pay special attention to the growth and
developmental impairment of various vital organs. Further
study is required to evaluate these agents for chronic pul-
monary hypertension and vascular remodeling in neonatal
animal models, and to establish their safety and appropriate
dose. Subsequent clinical trials can then be performed in care-
fully selected preterm and full term infants with chronic lung
disease and persistent pulmonary hypertension of newborn.
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